10058-F4: Next-Generation c-Myc-Max Dimerization Inhibitor for Apoptosis Research

Introduction

Targeting oncogenic transcription factors has long been a central objective in cancer research. Among these, c-Myc stands out due to its pivotal role in cell proliferation, metabolism, and survival. Dysregulation of c-Myc is a hallmark of numerous malignancies, including acute myeloid leukemia (AML) and prostate cancer. Despite its significance, c-Myc remains a challenging therapeutic target due to its intrinsically disordered structure and lack of a conventional binding pocket. 10058-F4 (SKU: A1169) has emerged as a potent, small-molecule c-Myc-Max dimerization inhibitor, offering a new avenue to dissect and disrupt c-Myc-driven oncogenic programs with high specificity and cell permeability. This article explores the latest mechanistic insights, technical applications, and future directions of 10058-F4, with a unique focus on its intersection with telomerase regulation and advanced apoptosis assays.

Mechanism of Action: Disrupting c-Myc/Max Heterodimers

The c-Myc/Max Heterodimer: A Central Hub in Oncogenic Signaling

c-Myc exerts its transcriptional activities primarily through dimerization with Max, forming the c-Myc-Max heterodimer that binds E-box sequences in DNA. This interaction is essential for activating genes involved in cell cycle progression, metabolism, and apoptosis evasion. Importantly, the c-Myc/Max dimerization interface is a validated target for therapeutic intervention.

10058-F4: Small-Molecule Disruption of Key Oncogenic Pathways

10058-F4 is a rationally designed, cell-permeable c-Myc inhibitor that selectively binds to the Myc bHLHZip domain, preventing heterodimerization with Max. By inhibiting this interaction, 10058-F4 blocks c-Myc's ability to bind DNA, suppressing downstream transcriptional programs. This mechanism leads to a marked decrease in c-Myc mRNA and protein levels, effectively shutting down c-Myc-driven gene networks critical for tumor progression.

What sets 10058-F4 apart is its efficacy in inducing cell cycle arrest and apoptosis via the mitochondrial pathway. The compound modulates Bcl-2 family proteins, prompting cytochrome C release and activation of caspases. This cascade culminates in robust apoptotic responses, especially in c-Myc-overexpressing AML cell lines (HL-60, U937, NB-4), where it induces dose- and time-dependent cell death. Notably, significant apoptosis is observed at 100 μM after 72 hours of treatment, highlighting its utility in apoptosis assay development and validation.

Expanding Horizons: 10058-F4 in Telomerase and DNA Repair Research

TERT Expression Regulation: Beyond Canonical c-Myc Pathways

Recent advances have illuminated the complex regulatory networks governing telomerase reverse transcriptase (TERT) expression. While c-Myc is a well-known activator of TERT transcription, emerging data suggest that DNA repair proteins also play pivotal roles. A groundbreaking study (Stern et al., 2024) demonstrated that apurinic/apyrimidinic endodeoxyribonuclease 2 (APEX2) is essential for efficient TERT expression in human embryonic stem cells and melanoma cells. Knockdown of APEX2, but not its paralog APEX1, dramatically reduced telomerase activity, implicating DNA repair pathways in the fine-tuning of telomerase gene regulation.

This finding provides a new context for the use of 10058-F4: by inhibiting c-Myc-mediated TERT activation while also allowing researchers to probe the interplay between c-Myc, DNA repair factors, and telomerase expression. This intersection is particularly relevant in cancer and stem cell biology, where telomere maintenance is tied to cellular immortality and genomic stability.

Novel Applications: Investigating c-Myc/Max Heterodimer Disruption in the Context of TERT Regulation

While previous reviews of 10058-F4 have addressed its impact on apoptosis and mitochondrial pathways, our focus here is to examine how this compound enables a systems-level interrogation of the c-Myc/Max–TERT–APEX2 regulatory axis. Researchers can leverage 10058-F4 to dissect:

• The direct effect of c-Myc/Max inhibition on TERT transcription and telomerase activity in cancer and stem cell models.
• How DNA repair proteins like APEX2 cooperate with or counterbalance c-Myc in regulating telomerase expression.
• The consequences of disrupting c-Myc-driven transcriptional programs on repetitive DNA elements (e.g., MIRs, Alu), as identified in the Stern et al. study.

This integrative approach offers a unique vantage point distinct from prior analyses, such as those in "10058-F4: Unraveling c-Myc/Max Disruption in Cancer and TERT Regulation", which primarily contextualized 10058-F4 within mitochondrial apoptosis and DNA repair. Here, we emphasize the compound's utility in mapping the complex regulatory network linking c-Myc, telomerase, and genomic stability.

Technical Profile: Properties, Handling, and Experimental Considerations

Chemical and Physical Properties

• Chemical Name: (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• Molecular Weight: 249.35
• Solubility: ≥24.9 mg/mL in DMSO, ≥2.64 mg/mL in ethanol; insoluble in water
• Formulation: Supplied as a solid; store at -20°C. Solutions should be freshly prepared and are not recommended for long-term storage.

Cellular and In Vivo Efficacy

10058-F4 displays robust cell permeability, making it ideal for in vitro and in vivo studies. In AML cell lines (HL-60, U937, NB-4), treatment results in significant apoptosis and cell cycle arrest. In vivo, intravenous administration to SCID mice bearing human prostate cancer xenografts (DU145, PC-3) led to variable tumor growth inhibition, underscoring the importance of context-specific factors in therapeutic response. These features position 10058-F4 as a leading tool for apoptosis assay development and translational cancer research.

Comparative Analysis: 10058-F4 Versus Alternative c-Myc Inhibition Strategies

Small-Molecule Versus Genetic Interventions

Traditional approaches to c-Myc inhibition have relied on genetic knockdown or antisense oligonucleotides, which often suffer from poor specificity, off-target effects, or delivery limitations. In contrast, 10058-F4 acts as a direct, small-molecule disruptor of the c-Myc-Max interaction, offering rapid, reversible, and tunable inhibition. This provides researchers with a more precise method to interrogate c-Myc function in real time and in diverse biological contexts.

Positioning Among Next-Generation Inhibitors

While other c-Myc/Max dimerization inhibitors are in development, 10058-F4 is distinguished by its cell permeability and extensive validation in both hematologic and solid tumor models. Its application in apoptosis assays and cancer biology research is well-established, yet its integration with telomerase and DNA repair studies remains an emerging frontier. Compared to previous reviews such as "10058-F4: Targeting c-Myc/Max Dimerization to Modulate Telomerase and Apoptosis", which highlighted mechanistic ties to TERT, this article emphasizes experimental strategies that leverage 10058-F4 for functional genomics and systems biology investigations.

Advanced Applications in Cancer and Stem Cell Biology

Acute Myeloid Leukemia and Prostate Cancer Xenograft Models

10058-F4 has demonstrated potent activity in AML, where c-Myc overexpression drives unchecked proliferation and resistance to apoptosis. Dose-dependent induction of cell death in HL-60, U937, and NB-4 cells positions it as a valuable agent for apoptosis assay calibration and for probing mitochondrial pathway dynamics. In prostate cancer xenograft models, variable tumor growth inhibition reflects the complexity of c-Myc-driven oncogenesis and the importance of combinatorial approaches.

Dissecting the c-Myc/Max–TERT–APEX2 Axis in Stem Cells

Building on the insights from Stern et al. (2024), 10058-F4 can be utilized to unravel how c-Myc/Max disruption impacts TERT expression in human embryonic stem cells, particularly in the context of DNA repair factor modulation. This is a novel application not extensively covered in prior literature, including "10058-F4: Novel Insights into c-Myc Inhibition and Mitochondrial Apoptosis", which primarily analyzed apoptosis mechanisms.

Interrogating Repetitive DNA Element Regulation

The Stern et al. study revealed that APEX2 binding in TERT intron 2 is enriched near mammalian-wide interspersed repeats (MIRs), suggesting a role for DNA repair in regulating gene expression from repetitive elements. Using 10058-F4, researchers can assess how c-Myc/Max inhibition influences the expression of genes embedded within or regulated by such elements, providing a new layer of complexity to cancer genomics studies.

Conclusion and Future Outlook

10058-F4 is more than a classic small-molecule c-Myc inhibitor; it is a versatile probe for dissecting the intricate regulatory networks underlying cancer and stem cell biology. Its capacity to disrupt c-Myc-Max dimerization, modulate mitochondrial apoptosis pathways, and intersect with telomerase and DNA repair regulation sets it apart from alternative tools. By enabling targeted, cell-permeable inhibition of c-Myc, 10058-F4 empowers researchers to pursue advanced apoptosis assays, map oncogenic signaling cascades, and explore emerging connections between transcription factor activity, DNA repair, and telomere maintenance.

As the field moves toward integrated, systems-level analysis of cancer pathways, the use of 10058-F4—in conjunction with genetic, epigenetic, and functional genomics tools—will be instrumental in revealing new therapeutic targets and diagnostic biomarkers. Future studies may uncover synergistic effects of c-Myc/Max inhibition with DNA repair modulation, paving the way for more effective combination therapies in oncology and regenerative medicine.

For further reading on the mechanistic depth and diverse applications of 10058-F4, see "10058-F4: Advanced Insights into c-Myc-Max Dimerization Inhibition". While those works explore foundational mechanisms, this article extends the discussion to systems biology and TERT regulation, offering a broader experimental framework for advanced users.